Please login to the form below

Not currently logged in
Email:
Password:

tenofovir disproxil

This page shows the latest tenofovir disproxil news and features for those working in and with pharma, biotech and healthcare.

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

The STR provided ‘effective’ and ‘durable’ viral suppression. Janssen’s darunavir-based single tablet regimen (STR) Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) showed a positive outcome in the treatment of HIV

Latest news

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    The EMA advisors issued a positive opinion for Vemlidy (tenofovir alafenamide) after data from two phase III studies showed Vemlidy to be superior to its predecessor Viread (tenofovir disproxil) in both

  • Research in HIV therapies Research in HIV therapies

    America. Tenofovir alafenamide (GS 7340) and tenofovir disproxil fumarate (TDF, Viread) are two prodrugs developed by Gilead and designed to have better oral availability and adverse events profiles than tenofovir. ... Tenofovir (Gilead, CONRAD) is a

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

The big issue
Whether you want to lead or follow, you need to understand the elephant in the C-suite...
INFOGRAPHIC 02: The Importance of clinical study websites
Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
Working with, Advocating for, and Empowering Patients
A holistic view of how to work with patients virtually...

Infographics